Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites

DNA Repair

Volumn 9, Issue 6, 2010, Pages 678-689

  Arlt, Martin F ^a   Glover, Thomas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Camptothecin; Common fragile sites; Replication stress; Topoisomerase I

Indexed keywords

APHIDICOLIN; ATR PROTEIN; BETULIC ACID; CAMPTOTHECIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1; CYCLINE; DNA; DNA TOPOISOMERASE; HELICASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; REPLICATION FACTOR A; SINGLE STRANDED DNA; ATM PROTEIN; ATR PROTEIN, HUMAN; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RPA2 PROTEIN, HUMAN; TRITERPENE;

ARTICLE; CELL CULTURE; CHROMOSOMAL INSTABILITY; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; METAPHASE CHROMOSOME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UBIQUITINATION; BIOSYNTHESIS; CELL NUCLEUS; DEFICIENCY; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION;

APHIDICOLIN; CAMPTOTHECIN; CELL CYCLE PROTEINS; CELL NUCLEUS; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITES; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA, SINGLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; REPLICATION PROTEIN A; TRITERPENES; UBIQUITINATION; ATAXIA TELANGIECTASIA MUTATED PROTEINS; TOPOISOMERASE I INHIBITORS;

EID: 77952581077     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2010.03.005     Document Type: Article

References (76)

1. Glover T.W., Arlt M.F., Casper A.M., and Durkin S.G. Mechanisms of common fragile site instability. Human Molecular Genetics 14 Spec No. 2 (2005) R197-R205
2. El-Achkar E., Gerbault-Seureau M., Muleris M., Dutrillaux B., and Debatisse M. Premature condensation induces breaks at the interface of early and late replicating chromosome bands bearing common fragile sites. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 18069-18074
3. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., and Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
4. Huang H., Qian J., Proffit J., Wilber K., Jenkins R., and Smith D.I. FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene 16 (1998) 2311-2319
5. Mishmar D., Rahat A., Scherer S.W., Nyakatura G., Hinzmann B., Kohwi Y., Mandel-Gutfroind Y., Lee J.R., Drescher B., Sas D.E., Margalit H., Platzer M., Weiss A., Tsui L.C., Rosenthal A., and Kerem B. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 8141-8146
6. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., and Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Research 60 (2000) 2140-2145
7. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., Woollatt E., Kremmidiotis G., Gardner A., Venter D., Baker E., and Richards R.I. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Human Molecular Genetics 9 (2000) 1651-1663
8. Arlt M.F., Miller D.E., Beer D.G., and Glover T.W. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes, Chromosomes & Cancer 33 (2002) 82-92
9. Morelli C., Karayianni E., Magnanini C., Mungall A.J., Thorland E., Negrini M., Smith D.I., and Barbanti-Brodano G. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 21 (2002) 7266-7276
10. Callahan G., Denison S.R., Phillips L.A., Shridhar V., and Smith D.I. Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 22 (2003) 590-601
11. Denison S.R., Wang F., Becker N.A., Schule B., Kock N., Phillips L.A., Klein C., and Smith D.I. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22 (2003) 8370-8378
12. Limongi M.Z., Pelliccia F., and Rocchi A. Characterization of the human common fragile site FRA2G. Genomics 81 (2003) 93-97
13. Rozier L., El-Achkar E., Apiou F., and Debatisse M. Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene 23 (2004) 6872-6880
14. Savelyeva L., Sagulenko E., Schmitt J.G., and Schwab M. The neurobeachin gene spans the common fragile site FRA13A. Human Genetics 118 (2006) 551-558
15. Durkin S.G., and Glover T.W. Chromosome fragile sites. Annual Review of Genetics (2007)
16. Glover T.W., Berger C., Coyle J., and Echo B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Human Genetics 67 (1984) 136-142
17. Jiang Y., Lucas I., Young D.J., Davis E.M., Karrison T., Rest J.S., and Le Beau M.M. Common fragile sites are characterized by histone hypoacetylation. Human Molecular Genetics 18 (2009) 4501-4512
18. Arlt M.F., Durkin S.G., Ragland R.L., and Glover T.W. Common fragile sites as targets for chromosome rearrangements. DNA Repair 5 (2006) 1126-1135
19. Durkin S.G., Ragland R.L., Arlt M.F., Mulle J.G., Warren S.T., and Glover T.W. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proceedings of the National Academy of Sciences of the United States of America 105 (2008) 246-251
20. Arlt M.F., Mulle J.G., Schaibley V.M., Ragland R.L., Durkin S.G., Warren S.T., and Glover T.W. Replication stress induces genome-wide copy number changes in human cells that resemble polymorphic and pathogenic variants. American Journal Of Human Genetics 84 (2009) 339-350
21. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
22. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio Jr. R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., and Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
23. Michael D., Beer D.G., Wilke C.W., Miller D.E., and Glover T.W. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15 (1997) 1653-1659
24. Huebner K., Hadaczek P., Siprashvili Z., Druck T., and Croce C.M. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochimica et Biophysica Acta 1332 (1997) M65-M70
25. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., Brenner A.J., and Aldaz C.M. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Research 61 (2001) 8068-8073
26. O'Keefe L.V., and Richards R.I. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Letters 232 (2006) 37-47
27. Casper A.M., Nghiem P., Arlt M.F., and Glover T.W. ATR regulates fragile site stability. Cell 111 (2002) 779-789
28. Arlt M.F., Xu B., Durkin S.G., Casper A.M., Kastan M.B., and Glover T.W. BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. Molecular and Cellular Biology 24 (2004) 6701-6709
29. Durkin S.G., Arlt M.F., Howlett N.G., and Glover T.W. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 25 (2006) 4381-4388
30. Howlett N.G., Taniguchi T., Durkin S.G., D'Andrea A.D., and Glover T.W. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Human Molecular Genetics 14 (2005) 693-701
31. Schwartz M., Zlotorynski E., Goldberg M., Ozeri E., Rahat A., le Sage C., Chen B.P., Chen D.J., Agami R., and Kerem B. Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability. Genes & Development 19 (2005) 2715-2726
32. Hellman A., Rahat A., Scherer S.W., Darvasi A., Tsui L.C., and Kerem B. Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Molecular and Cellular Biology 20 (2000) 4420-4427
33. Palakodeti A., Han Y., Jiang Y., and Le Beau M.M. The role of late/slow replication of the FRA16D in common fragile site induction. Genes, Chromosomes & Cancer 39 (2004) 71-76
34. Stivers J.T., Harris T.K., and Mildvan A.S. Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation. Biochemistry 36 (1997) 5212-5222
35. Thomas C.J., Rahier N.J., and Hecht S.M. Camptothecin: current perspectives. Bioorganic & Medicinal Chemistry 12 (2004) 1585-1604
36. Gambus A., Jones R.C., Sanchez-Diaz A., Kanemaki M., van Deursen F., Edmondson R.D., and Labib K. GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nature Cell Biology 8 (2006) 358-366
37. Garcia-Carbonero R., and Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Research 8 (2002) 641-661
38. Coll J.M., Hickey R.J., Wei Y., and Malkas L.H. The human cell multiprotein DNA replication complex (MRC): the effect of camptothecin on its ability to support in vitro DNA synthesis. Cancer Chemotherapy and Pharmacology 39 (1996) 97-102
39. Hsiang Y.H., and Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Research 48 (1988) 1722-1726
40. Pommier Y., Pourquier P., Fan Y., and Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochimica et Biophysica Acta 1400 (1998) 83-105
41. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews 6 (2006) 789-802
42. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., and Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Molecular and Cellular Biology 20 (2000) 3977-3987
43. Holm C., Covey J.M., Kerrigan D., and Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Research 49 (1989) 6365-6368
44. O'Connor P.M., Nieves-Neira W., Kerrigan D., Bertrand R., Goldman J., Kohn K.W., and Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Communications 3 (1991) 233-240
45. Shao R.G., Cao C.X., Zhang H., Kohn K.W., Wold M.S., and Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. The EMBO Journal 18 (1999) 1397-1406
46. Wilke C.M., Guo S.W., Hall B.K., Boldog F., Gemmill R.M., Chandrasekharappa S.C., Barcroft C.L., Drabkin H.A., and Glover T.W. Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both FRA3B and the t(3;8) associated with hereditary renal cell carcinoma. Genomics 22 (1994) 319-326
47. Anton M., and Graham F.L. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. Journal of Virology 69 (1995) 4600-4606
48. Syrovets T., Buchele B., Gedig E., Slupsky J.R., and Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Molecular Pharmacology 58 (2000) 71-81
49. Ganguly A., Das B., Roy A., Sen N., Dasgupta S.B., Mukhopadhayay S., and Majumder H.K. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Research 67 (2007) 11848-11858
50. Manthey K.C., Opiyo S., Glanzer J.G., Dimitrova D., Elliott J., and Oakley G.G. NBS1 mediates ATR-dependent RPA hyperphosphorylation following replication-fork stall and collapse. Journal of Cell Science 120 (2007) 4221-4229
51. Sakasai R., Shinohe K., Ichijima Y., Okita N., Shibata A., Asahina K., and Teraoka H. Differential involvement of phosphatidylinositol 3-kinase-related protein kinases in hyperphosphorylation of replication protein A2 in response to replication-mediated DNA double-strand breaks. Genes Cells 11 (2006) 237-246
52. Nuss J.E., Patrick S.M., Oakley G.G., Alter G.M., Robison J.G., Dixon K., and Turchi J.J. DNA damage induced hyperphosphorylation of replication protein A. 1. Identification of novel sites of phosphorylation in response to DNA damage. Biochemistry 44 (2005) 8428-8437
53. Anantha R.W., Vassin V.M., and Borowiec J.A. Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair. The Journal of Biological Chemistry 282 (2007) 35910-35923
54. Olson E., Nievera C.J., Klimovich V., Fanning E., and Wu X. RPA2 is a direct downstream target for ATR to regulate the S-phase checkpoint. The Journal of Biological Chemistry 281 (2006) 39517-39533
55. Wu X., Yang Z., Liu Y., and Zou Y. Preferential localization of hyperphosphorylated replication protein A to double-strand break repair and checkpoint complexes upon DNA damage. The Biochemical Journal 391 (2005) 473-480
56. Capasso H., Palermo C., Wan S., Rao H., John U.P., O'Connell M.J., and Walworth N.C. Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. Journal of Cell Science 115 (2002) 4555-4564
57. Byun T.S., Pacek M., Yee M.C., Walter J.C., and Cimprich K.A. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes & Development 19 (2005) 1040-1052
58. Horwitz S.B., Chang C.K., and Grollman A.P. Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. Molecular Pharmacology 7 (1971) 632-644
59. Tsao Y.P., D'Arpa P., and Liu L.F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Research 52 (1992) 1823-1829
60. Rodriguez R., and Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Molecular Biology of the Cell 17 (2006) 402-412
61. Chang D.J., Lupardus P.J., and Cimprich K.A. Monoubiquitination of proliferating cell nuclear antigen induced by stalled replication requires uncoupling of DNA polymerase and mini-chromosome maintenance helicase activities. The Journal of Biological Chemistry 281 (2006) 32081-32088
62. Stelter P., and Ulrich H.D. Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation. Nature 425 (2003) 188-191
63. Hoege C., Pfander B., Moldovan G.L., Pyrowolakis G., and Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419 (2002) 135-141
64. Leach C.A., and Michael W.M. Ubiquitin/SUMO modification of PCNA promotes replication fork progression in Xenopus laevis egg extracts. The Journal of Cell Biology 171 (2005) 947-954
65. Niimi A., Brown S., Sabbioneda S., Kannouche P.L., Scott A., Yasui A., Green C.M., and Lehmann A.R. Regulation of proliferating cell nuclear antigen ubiquitination in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 105 (2008) 16125-16130
66. Dubois M.F., Nguyen V.T., Bellier S., and Bensaude O. Inhibitors of transcription such as 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole and isoquinoline sulfonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit. The Journal of Biological Chemistry 269 (1994) 13331-13336
67. Ikegami S., Taguchi T., Ohashi M., Oguro M., Nagano H., and Mano Y. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. Nature 275 (1978) 458-460
68. Lee M.Y., Tan C.K., Downey K.M., and So A.G. Structural and functional properties of calf thymus DNA polymerase delta. Progress in Nucleic Acid Research and Molecular Biology 26 (1981) 83-96
69. Goscin L.P., and Byrnes J.J. DNA polymerase delta: one polypeptide, two activities. Biochemistry 21 (1982) 2513-2518
70. Walter J., and Newport J. Initiation of eukaryotic DNA replication: origin unwinding and sequential chromatin association of Cdc45, RPA, and DNA polymerase alpha. Molecular Cell 5 (2000) 617-627
71. Pacek M., and Walter J.C. A requirement for MCM7 and Cdc45 in chromosome unwinding during eukaryotic DNA replication. The EMBO Journal 23 (2004) 3667-3676
72. Pacek M., Tutter A.V., Kubota Y., Takisawa H., and Walter J.C. Localization of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA replication. Molecular Cell 21 (2006) 581-587
73. Gorisch S.M., Sporbert A., Stear J.H., Grunewald I., Nowak D., Warbrick E., Leonhardt H., and Cardoso M.C. Uncoupling the replication machinery: replication fork progression in the absence of processive DNA synthesis. Cell Cycle 7 (2008) 1983-1990
74. Svoboda D.L., and Vos J.M. Differential replication of a single, UV-induced lesion in the leading or lagging strand by a human cell extract: fork uncoupling or gap formation. Proceedings of the National Academy of Sciences of the United States of America 92 (1995) 11975-11979
75. McInerney P., and O'Donnell M. Functional uncoupling of twin polymerases: mechanism of polymerase dissociation from a lagging-strand block. The Journal of Biological Chemistry 279 (2004) 21543-21551
76. Lopes M., Foiani M., and Sogo J.M. Multiple mechanisms control chromosome integrity after replication fork uncoupling and restart at irreparable UV lesions. Molecular Cell 21 (2006) 15-27